| Followers | 139 |
| Posts | 9298 |
| Boards Moderated | 1 |
| Alias Born | 04/28/2011 |
Thursday, August 01, 2024 8:09:06 AM
Well 95% of that is way over my head but it looks good Lol.
Thanks for the update!
Thanks for the update!
Recent CCCC News
- C4 Therapeutics to Participate in Upcoming Conferences • GlobeNewswire Inc. • 05/20/2026 11:00:00 AM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 05/19/2026 08:09:36 PM
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/18/2026 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:03:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 05/15/2026 12:10:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/12/2026 11:07:28 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 11:05:23 AM
- C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 05/12/2026 11:00:00 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/29/2026 11:03:45 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/29/2026 11:02:40 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/29/2026 11:00:43 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2026 11:17:23 AM
- C4 Therapeutics shares jump on expanded oncology collaboration with Roche • IH Market News • 04/09/2026 02:57:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2026 11:07:35 AM
- C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs) • GlobeNewswire Inc. • 04/09/2026 10:59:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 02:45:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 02:45:44 PM
- C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma • GlobeNewswire Inc. • 03/25/2026 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/09/2026 08:20:02 PM
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/09/2026 08:01:00 PM
- Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types • PR Newswire (Canada) • 03/05/2026 02:00:00 PM
- Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types • PR Newswire (US) • 03/05/2026 02:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 12:49:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 12:09:49 PM
- C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 02/26/2026 12:00:00 PM
